logo

For the Inventor, By the Inventor

Parkville, Australia

Csl Limited


USPTO Granted Patents = 123

% Expired Patents = 17.9



Trademarks = 10

Forward Citations = 622

Loading Chart...
Loading Chart...

155 inventors (with patents filed for the assignee):

goldMedal Andrew Donald Nash (19 out of 29 patents)

silverMedal Con Panousis (16 out of 19 patents)

bronzeMedal Gary Lee Warren (11 out of 11 patents)

4.  Yvonne Vucica (11 out of 11 patents)

5.  Manuel Baca (11 out of 33 patents)

6.  Veronika Rayzman (9 out of 9 patents)

7.  Michael Wilson (7 out of 10 patents)

8.  Marc Nolte (7 out of 24 patents)

9.  William Strohl (7 out of 29 patents)

10.  Matthew Hardy (7 out of 9 patents)

11.  Kirsten Edwards (7 out of 7 patents)

12.  Hubert Metzner (7 out of 28 patents)

13.  Louis Jerry Fabri (7 out of 16 patents)

14.  Zhiqiang An (7 out of 43 patents)

15.  Ian George Barr (7 out of 8 patents)


Core Competencies:
Therapeutic Antibodies
Diabetic Nephropathy
Inflammatory Bowel Disease
Neurological Conditions
Apolipoprotein A-I
VEGF-B Signaling
High Density Lipoprotein
G-CSF Receptor
Factor VIII
Interleukin-13
Antibody Purification
Immune Response

123 patents:

1. 12630616 - Complement C2 Binding Proteins and Uses Thereof (2026-05-19),
2. 12281160 - Method of treating asthma (2025-04-21),
3. 12264202 - Methods of reducing or hindering development of ischemia-reperfusion injury due to kidney transplantation with an antibody that inhibits granulocyte-colony stimulating factor (G-CSF) signaling (2025-04-01),
4. 12071484 - Nucleic acids encoding antibodies against human granulocyte-colony stimulating factor receptor (G-CSFR) and method of expressing encoded protein (2024-08-27),
5. 11957731 - Reconstituted HDL formulation (2024-04-16),
6. 11840573 - CD131 binding proteins and uses thereof (2023-12-12),
7. 11732028 - Contaminant removal method (2023-08-22),
8. 11723953 - Reconstituted high density lipoprotein formulation and production method thereof (2023-08-15),
9. 11510968 - Method for improving the stability of purified Factor VIII after reconstitution (2022-11-29),
10. 11505619 - Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease (2022-11-22),
11. 11466073 - Human serum albumin variants and uses thereof (2022-10-11),
12. 11464828 - Reconstituted HDL formulation (2022-10-11),
13. 11345759 - Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies (2022-05-31),
14. 11279750 - Process for preparing apolipoprotein A-I (Apo A-I) (2022-03-22),
15. 11261243 - Methods of treating diabetic nephropathy by administering an anti-vegf-b (vascular endothelial growth factor-b) antibody (2022-03-01),
CSL Limited is a global biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious medical conditions. With operations in over 30 countries and a diverse product portfolio, CSL's focus areas include vaccines, plasma protein biotherapeutics, and recombinant proteins. The company is committed to advancing innovative solutions in healthcare and improving patient outcomes.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Csl Limited
123 Patents

#1 in Parkville

#22 in Australia

#6,499 in the World

Parkville, AU
Parkville, Australia

Csl Limited

Forward Citations = 622

155 inventors:

goldMedal Andrew Donald Nash (19 out of 29 patents)

silverMedal Con Panousis (16 out of 19 patents)

bronzeMedal Gary Lee Warren (11 out of 11 patents)

4.  Yvonne Vucica (11 out of 11 patents)

5.  Manuel Baca (11 out of 33 patents)

Please report any incorrect information to [email protected]
Loading…